Ozempic vs Mounjaro

The genuine comparison in this class: one hormone against two. Tirzepatide produced larger average reductions in trials, but both are effective and individual response varies more than the trial gap.

Where they genuinely differ

These are different molecules, so this is a real comparison rather than a comparison of labels.

• Target. Ozempic contains semaglutide and Mounjaro contains tirzepatide. Tirzepatide is the outlier in this class: it activates the receptor for a second gut hormone, GIP, alongside the GLP-1 receptor. Everything else acts on GLP-1 alone.
• Clearance. Ozempic has a half-life of ~160 hours (about 7 days); Mounjaro, ~5 days. That single number sets the dosing interval, how long escalation takes, how forgiving a missed dose is, and how gradually the effect fades when you stop.
• Ladder. Ozempic climbs through 4 steps; Mounjaro through 6. More rungs means smaller jumps and more places to pause.

Ozempic

Ozempic is semaglutide, licensed for type 2 diabetes. It is the product that made this class famous, and much of the confusion around GLP-1 medicines traces back to it: the same molecule is also sold as Wegovy® for weight management, at a higher maximum dose and under a different label.

The practical difference between Ozempic and Wegovy is the ceiling. Ozempic tops out at 2 mg weekly; Wegovy goes to 2.4 mg and is licensed for weight management rather than glucose control. The pens are also built differently — an Ozempic pen delivers several doses from one cartridge, which is why the strength is described per dose rather than per pen.

Full Ozempic reference · dosing · side effects

Mounjaro

Mounjaro is tirzepatide, and it is the one genuine mechanistic departure in this class. Every other product acts on the GLP-1 receptor alone; tirzepatide also activates the receptor for a second gut hormone, GIP.

In head-to-head trials the dual agonist produced larger average weight reductions than semaglutide. That is an average across a trial population, not a prediction about you — response varies widely, and the better trial number does not always translate into the better medicine for an individual.

Full Mounjaro reference · dosing · side effects

Side effects compared

The honest answer is that the gastrointestinal profile is broadly similar across this whole class, because it comes from the same mechanism: a stomach that empties more slowly. Nausea, early fullness, constipation and reflux appear on every label here.

What differs is intensity, and intensity tracks dose and effect size rather than the specific molecule. A product that produces a larger average metabolic change tends to produce more of the gut effects along with it. Comparing two products at the doses people actually take is therefore more informative than comparing them at their maximums — and both are less informative than your own first two dose increases.

Which is more effective?

Trials give averages, and averages are the right way to compare products and the wrong way to predict an individual. Where head-to-head data exist, they show real differences between molecules — but the spread of individual responses within either arm is wider than the gap between the arms.

What that means in practice: the product with the better trial number is a reasonable starting assumption and a poor guarantee. Plenty of people do better on the one the numbers favour less, and the only way to find out which group you are in is to take one properly — at a maintenance dose, for long enough, with the schedule kept.

Switching between them

A supervised switch normally means starting the new product near the bottom of its own ladder even if you were at the top of the previous one, and accepting a few weeks of reduced effect while levels rebuild. Where the two products share a molecule, the switch is simpler — but it is still a prescribing decision, because the licence and the ceiling change with it.

Availability

Which of these you can actually obtain depends on where you live. Licences differ between regions, brand names differ for identical molecules, and supply has been intermittent across this whole class. A comparison that concludes one product is preferable is of limited use if your pharmacy cannot get it.

Common questions

How long does it take to reach the maintenance dose of Ozempic?

At minimum five weeks to reach 0.5 mg, and a further four weeks for each step after that. Someone going all the way to 2 mg is looking at roughly thirteen weeks. Most people never need the top dose — 0.5 mg and 1 mg are both recognised maintenance doses, and the target is glucose control rather than the highest number on the pen.

Does Ozempic cause hair loss?

Hair shedding is reported, but the mechanism most likely is not the drug itself — it is telogen effluvium, the temporary shedding that follows rapid weight loss or a sharp drop in protein and micronutrient intake. It is usually reversible. Keeping protein intake up is the practical response.

How long to reach 15 mg of Mounjaro?

Twenty-one weeks at the minimum pace — six rungs, at least four weeks each. But 15 mg is a maximum, not a target. 5 mg and 10 mg are both recognised maintenance doses and many people settle at one of them.

Why do I feel sulphur burps on Mounjaro?

Delayed gastric emptying with more pressure behind it. Unpleasant, common, and usually improved by eating earlier in the evening, smaller portions, and staying upright after meals.

Cost, coverage and supply

Price is frequently the deciding factor and it is the one this site can say least about, because it varies by country, by health system, by insurer and by indication. Two things are worth knowing in general terms.

First, coverage usually follows the licence. A product licensed for diabetes is often funded for diabetes and not for weight management, even when the molecule is identical to one that is. That is why the same substance can be straightforward to obtain under one brand name and difficult under another.

Second, supply across this whole class has been intermittent, and shortages have moved between products rather than affecting all of them at once. A plan that depends on one specific brand being available every month is more fragile than it looks. It is worth asking your prescriber what the alternative would be if your product became unavailable — before it does.

Questions worth asking about this choice

• Which of these is licensed for my indication where I live?
• Which one can you actually obtain reliably at the moment?
• Is there a reason from my history to prefer one over the other?
• If this one does not suit me, what would we try next, and would I have to start the ladder again?
• What would we regard as this having worked, and by when?

That last question is the one people most often leave the room without having asked, and it is the one that prevents a treatment drifting for a year without anyone deciding whether it is working.

What the choice actually depends on

Not, mostly, on which of these two is better. It depends on your indication, your medical history, what is licensed and funded where you live, what your prescriber can obtain, and which routine you can realistically sustain for a year. A table cannot weigh those.

What a table can do is tell you what you are being offered and what questions to ask about it — which turns a consultation into a shorter and more useful conversation than it would otherwise be.